<code id='7C05D97004'></code><style id='7C05D97004'></style>
    • <acronym id='7C05D97004'></acronym>
      <center id='7C05D97004'><center id='7C05D97004'><tfoot id='7C05D97004'></tfoot></center><abbr id='7C05D97004'><dir id='7C05D97004'><tfoot id='7C05D97004'></tfoot><noframes id='7C05D97004'>

    • <optgroup id='7C05D97004'><strike id='7C05D97004'><sup id='7C05D97004'></sup></strike><code id='7C05D97004'></code></optgroup>
        1. <b id='7C05D97004'><label id='7C05D97004'><select id='7C05D97004'><dt id='7C05D97004'><span id='7C05D97004'></span></dt></select></label></b><u id='7C05D97004'></u>
          <i id='7C05D97004'><strike id='7C05D97004'><tt id='7C05D97004'><pre id='7C05D97004'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion